Related Experiment Video
Updated: Sep 21, 2025

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Dihydromyricetin Improves High-Fat Diet-Induced Hyperglycemia through ILC3 Activation via a SIRT3-Dependent Mechanism
Jie Zhou1, Pengfei Hou1, Yu Yao1
1Research Center for Nutrition and Food Safety, Chongqing Key Laboratory of Nutrition and Food Safety, Chongqing Medical Nutrition Research Center, Institute of Military Preventive Medicine, Third Military Medical University, Chongqing, 400038, P. R. China.
Scope:
Previous studies indicate that dihydromyricetin (DHM) effectively improved glucose homeostasis and alleviated insulin resistance in population-intervened trials, yet the underlying mechanism remains obscure.
Methods And Results:
Wild-type male mice and recombinase activating gene 1(Rag1)-/- mice (lacking adaptive immunity lymphocytes) are fed with control, high-fat diet (HFD), or HFD+DHM diets for 8 weeks. DHM effectively protects HFD feeding mice against hyperglycemia by promoting group 3 innate lymphoid cells (ILC3s) cells proliferation and interleukin 22 (IL-22) production. Furthermore, IL-22 secretion induced by DHM increases the expression levels of the tight junction (TJs) molecules to protect the intestinal barrier integrity, thereby decreasing the level of lipopolysaccharides (LPS), an endotoxin that is involved in the regulation of chronic tissue inflammation and insulin resistance. In addition, silent mating-type information regulation 2 homolog 3 (SIRT3) deficiency results in more serious obesity and intestinal barrier damage following HFD feeding and abolished DHM-mediated increase in IL-22 expression levels of ILC3 cells in SIRT3 knockout (SIRT3KO) mice. DHM reduces metabolic stress and enhances mitochondrial respiratory capacity to promote cell proliferation and IL-22 secretion by activating SIRT3 in ILC3 cells CONCLUSIONS: DHM improves IL-22 production of ILC3 cells and subsequently inhibits intestinal barrier dysfunction to alleviate hyperglycemia partially mediated by SIRT3.
More Related Videos
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Insulin: The Receptor and Signaling Pathways
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Cholesterol: Significance and Regulation
Considering cholesterol and...